Across the entire genome, we identify the genetic pattern of a patient’s cancer using thousands of data points and our proprietary computation and AI methods. Our technology allows for significantly higher sensitivity, 100X more than any other alternative, while only using small samples of blood (1-2mL). The large genomic signature allows accurate and robust tracking of the tumor progression as it evolves during the patient treatment and follow up period. Our technology also eliminates the need to develop a patient-specific assay, enabling high performance monitoring with reduced complexity and rapid turnaround.
Our technology has been validated with more than 1000 samples processed in longitudinal studies with top global clinical centers, C2i has now established partnerships with leading cancer sequencing centers across the world, with active clinical trials conducted at the US, EU and Asia, covering a variety of solid cancer types.